FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Wright Frank J				AI	2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC ALXN]										tionship of Reporting all applicable) Director Officer (give title		10% Othe	Owner r (specify		
(Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS 352 KNOTTER DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 02/06/2014										SVP	w) below) P, President Alxn Pharm Int		′	
(Street) CHESHIRE CT 06410 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									i. Indiv ine) X	Forn Forn	al or Joint/Group Filing (Check Applicable form filed by One Reporting Person form filed by More than One Reporting ferson			
		Tabl	e I - No	n-Deri\	/ative	Sec	uritie	s Ac	quired	, Dis	posed o	f, oı	Ber	nefici	ally	Owne	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				4 and 5) S		ount of ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
		Code	v	Amount			nt (A)		Price			action(s) 3 and 4)		(Instr. 4)						
Common Stock, par value \$.0001 per share 02/06/2					/2014	014		А		6,068(1))	A	\$0		20,768		D			
Common Stock, par value \$.0001 per share 02/07/2				/2014	014		S		1,090(2))	D	\$155.55		19,678		D				
Common Stock, par value \$.0001 per share 02/07/2				/2014	014		S		8(2)		D	\$158.69		19,670		D				
		Та									osed of, onvertib					vned				
1. Title of Derivative Security (Instr. 3)	Conversion or Exercise (Month/Day/Year) Frice of Derivative Security Execution Date, if any (Month/Day/Year) 2		4. Transa Code (8)		of Deriv Secu Acqu (A) o Dispo	r osed) r. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		nstr. 3			9. Number of derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)				

Explanation of Responses:

- 1. On February 6, 2013, the reporting person was granted a performance award representing the right to receive 8,290 shares of common stock upon achievement of certain performance targets and on February 6, 2014 the Compensation Committee certified achievement of the performance targets. 1/3 of such shares vested on February 6, 2014 and 1/3 vest on each subsequent anniversary.
- 2. This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units.

Remarks:

/s/ Michael Greco Attorney-in-

02/10/2014

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.